Vimarsana
Biggest News Aggregation in the World

Plenary Series Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Plenary Series Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Plenary Series Program Today - Breaking & Trending Today

Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer - Vimarsana News

Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer

Published: July 25, 2023

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...

Source: prnewswire.com
Related Topics:
Region FlamandeSouth KoreaUnited KingdomHong KongUnited StatesKyongsang BuktoReshma RangwalaBrian SlomovitzLuxembourg Gynaecological Oncology GroupFoundation IncAmerican Cancer SocietyAmerican Society Of Clinical OncologyGynecologic Oncology GroupMount Sinai Medical CenterWorld Health OrganizationSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncInformation DepartmentDrug AdministrationInternational Agency For Research On CancerPartners IncLeuven Cancer InstituteNational Cancer InstituteEuropean Network Of Gynaecological Oncological Trial GroupsUniversity Of Leuven
Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors - Vimarsana News

Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors

Published: April 26, 2023

/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, announced today the Journal of Clinical Oncology published...

Source: prnewswire.com
Related Topics:
United StatesAlan SandlerBasu MallickMeeting ProgramMirati Therapeutics IncPrnewswire Mirati Therapeutics IncUniversity Of Texas Md Anderson Cancer CenterExchange CommissionPlenary Series ProgramRapid CommunicationsNational Comprehensive Center NetworkAmerican Society Of Clinical OncologyClinical OncologyRapid CommunicationAmerican SocietyPlenary SeriesCentral Nervous SystemShubham PantMirati TherapeuticsCseries ProgramSafety Of AdagrasibPatients With Advanced Solid Tumors HarboringProgram GuideAccelerated ApprovalTime Oncology Review
Domvanalimab-Containing Regimens Show Activity in PD-L1-High NSCLC - Vimarsana News

Domvanalimab-Containing Regimens Show Activity in PD-L1-High NSCLC

Published: December 28, 2022

Domvanalimab-containing treatment regimens may improve outcomes, when compared with zimberelimab alone, in patients with PD-L1-high NSCLC.

Source: cancertherapyadvisor.com
Related Topics:
United StatesMelissa JohnsonPlenary Series ProgramSarah Cannon Cancer CenterCseries Program